Cell survival & anti-apoptosis

The lane

Status: Narrowed. Several attempts failed; work continues in a smaller group or with a different drug.
Verdict: Blocking cell-death signals failed (CEP-1347, TCH346, nilotinib); c-Abl inhibitors keep going but vodobatinib (PROSEEK) was no better than placebo and was stopped, risvodetinib missed its 12-week measure, and radotinib (primary follow-up complete Sept 2026) reports in 2027.
Family: Housekeeping
Landmarks: 14 in this lane. Advanced 1 · Open 6 · Pending 2 · Superseded 1 · Dead end 4

The verdict and status come from the project's branches.yaml and use research wording.

14 landmarks drawn in this lane, oldest first. Select a column heading to sort.

TCH346 (GAPDH binder)	2002–2006	Trial in people	Did not work	2	301	19 Oct 2026	2
PRECEPT: CEP-1347	2007	Trial in people	Did not work	2	806	19 Oct 2026	3
c-Abl switches off parkin in Parkinson's brain	2010–2011	Discovery	Confirmed and built on	–	–	19 Oct 2026	3
PARIS builds up when parkin fails	2011	Discovery	Still being studied	–	–	19 Oct 2026	4
Ferroptosis in dopamine neurons	2012–2016	Discovery	Still being studied	–	–	19 Oct 2026	4
The c-Abl idea: mouse studies and a 12-person pilot	2014–2015	Discovery	Replaced by a better idea	–	–	19 Oct 2026	2
Nilotinib: Georgetown and NILO-PD	2017–2021	Trial in people	Did not work	2	151	19 Oct 2026	3
Synuclein fibrils kill via PARP1	2018	Discovery	Still being studied	–	–	20 Oct 2026	3
Necroptosis in Parkinson's models	2018–2020	Lab study (cells or animals)	Still being studied	–	–	20 Oct 2026	3
Low-dose lithium (Buffalo)	2019–2026	Trial in people	Result due Nov 2026	1	15	22 Oct 2026	3
Vodobatinib: PROSEEK Phase 2	2019–2026	Trial in people	Did not work	2	513	19 Oct 2026	3
Radotinib Phase 2 (France)	2021–2027	Trial in people	Result due Apr 2027	2	43	22 Oct 2026	4
Risvodetinib (c-Abl), Phase 2 "201"	2023–2025	Trial in people	Mixed or early results	2	137	19 Oct 2026	5
Fasudil (ROCK-PD)	2023–2026	Trial in people	Mixed or early results	2	81	19 Oct 2026	4